Pegylation
Pegylation - Related Videos
10:18
Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry
0 Views •
Cited by 12 •
2018
Here, we present a procedure to fluorescently functionalize the disulfides on Qβ VLP with dibromomaleimide. We describe Qβ expression and purification, the synthesis of dibromomaleimide-functionalized molecules, and the conjugation reaction between dibromomaleimide and Qβ. The resulting yellow fluorescent conjugated particle can be used as a fluorescence probe inside cells.
08:28
Acyl-PEGyl Exchange Gel Shift Assay for Quantitative Determination of Palmitoylation of Brain Membrane Proteins
0 Views •
Cited by 7 •
2020
Palmitoylation entails the incorporation of a 16-carbon palmitate moiety to cysteine residues of target proteins in a reversible manner. Here, we describe a biochemical approach, the acyl-PEGyl exchange gel shift (APEGS) assay, to investigate the palmitoylation state of any protein of interest in mouse brain lysates.
09:24
Synthesis, Hemoglobin Encapsulation and Biorthogonal PEGylation in Hierarchically Porous UiO-66 Nanoparticles for Oxygen Delivery Applications
0 Views •
2026
This protocol details the synthesis, hemoglobin encapsulation, and surface PEGylation of hierarchically porous UiO-66 nanoparticles designed for oxygen delivery. The procedure combines defect engineering with strain-promoted biorthogonal conjugation to generate highly permeable and physiologically stable carriers suitable for biomedical applications.
10:35
Surface Passivation for Single-molecule Protein Studies
0 Views •
Cited by 270 •
2014
We describe a method for passivating a glass surface using polyethylene glycol (PEG). This protocol covers surface cleaning, surface functionalization, and PEG coating. We introduce a new strategy for treating the surface with PEG molecules over two rounds, which yields superior quality of passivation compared to existing methods.
03:51
Fluorescent Functionalization of Virus-Like Particles via Disulfide Re-bridging
0 Views •
2026
Source: Chen, Z., et al. Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry. J. Vis. Exp. (2018)This video demonstrates the fluorescent functionalization of virus-like particles by re-bridging reduced disulfides with a polyethylene glycol (PEG) linker, producing stable, trackable conjugates suitable for cellular imaging and targeted delivery in biomedical applications.
FAQs
The attached PEG chains form a hydrated polymer layer around the therapeutic molecule. This layer increases its apparent size and can reduce access by degrading enzymes and components involved in immune recognition. As a result, the modified molecule may remain stable for longer and circulate for an extended period, although the outcome depends on how the PEG is attached.
PEG chain size, attachment site, linker chemistry, and product heterogeneity are central design variables. Chain size affects the molecule’s apparent dimensions, while the attachment site and linker influence how the modification interacts with the therapeutic structure. Controlling these factors helps bioengineers balance improved stability and circulation with the properties required for biological activity.
Product heterogeneity means that a preparation contains molecules with different PEG attachment patterns or modification levels. Such variation can produce nonuniform physicochemical and biological behavior across the product. For this reason, controlling the attachment site, linker chemistry, and PEG chain characteristics is important when seeking consistent performance, predictable circulation, and reliable behavior in bioengineering applications.
A typical workflow begins by selecting a therapeutic molecule and a reactive PEG derivative suited to its functional groups. The derivative is then used to create covalent attachment, followed by attention to the resulting PEG chain characteristics, linker chemistry, attachment site, and degree of product heterogeneity. These choices determine whether the modified molecule meets the intended stability and delivery goals.
Researchers may consider Pegylation when a protein, peptide, nucleic acid, or drug molecule needs improved solubility, greater resistance to enzymatic degradation, or reduced immune recognition. In bioengineering, the approach can also support longer circulation and less frequent dosing. It is therefore relevant to therapeutic biologics and drug-delivery systems whose performance depends on stability and residence time.
By modifying apparent size and shielding the therapeutic molecule, Pegylation can extend circulation time and potentially reduce dosing frequency. The actual benefit is not uniform because PEG chain size, attachment site, linker chemistry, and product heterogeneity influence the result. These variables must be considered when designing biologics or delivery systems for improved persistence and stability.